Source: IE
Context: A new Alzheimer’s drug, donanemab, has received support from an FDA advisory committee, moving closer to approval.
- Intended for early-stage Alzheimer’s, it shows significant slowing of cognitive decline.
- The drug works by targeting amyloid beta protein deposits in the brain.
Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and is the most common type of dementia.
It’s characterized by changes in the brain that lead to protein deposits, brain shrinkage, and eventually cell death.
